Based in Ahmedabad, India, Intas Pharmaceuticals Limited engages in the manufacture, marketing, distribution, and sale of finished pharmaceutical formulations, active pharmaceutical ingredients, medical appliances, and medical devices worldwide.
The company provides products in various therapeutic areas, such as neurology, psychiatry, cardiology, diabetology, urology, nephrology, and pain management. It offers a portfolio of biosimilar products across microbial and mammalian cell culture products, such as Neukine, Erykine, Intalfa, Pegasta, Terifrac, Mabtas, and Folisurge, as well as operates in the field of plasma-derived products and therapies.
Intas shot into the limelight in October 2016 when they scooped up Teva’s assets in the UK and Ireland in a $764 million deal.